{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:58:55Z","timestamp":1781240335824,"version":"3.54.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Deficient mismatch repair (dMMR) is a key molecular subtype of colorectal cancer (CRC) with significant prognostic and therapeutic implications, particularly regarding response to immunotherapy. The prevalence and clinicopathological features of dMMR CRC can vary by population. This research aimed to assess the prevalence of MMR protein deficiency and its relation to clinicopathological characteristics in Chinese CRC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty patients with primary colorectal adenocarcinoma who underwent radical surgical resection were enrolled. Immunohistochemistry (IHC) was used to detect the expression of the four MMR proteins (MLH1, MSH2, MSH6, and PMS2). Patients were classified as dMMR or pMMR. Associations between MMR status and various clinicopathological features, including tumor location, differentiation, histology, and lymph node metastasis, were analyzed using Fisher\u2019s exact or chi-square tests, Spearman correlation, and simplified multivariable logistic regression with forward stepwise selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 80 patients, 18 (22.5%) were identified as dMMR. The most common deficiency pattern was isolated PMS2 loss (50.0% of dMMR cases), followed by combined loss of MLH1\/PMS2 (33.3%). Compared to the pMMR group, dMMR CRCs were significantly more likely to be located in the right colon (61.1% vs. 22.6%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), be poorly differentiated (50.0% vs. 19.4%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.009), exhibit mucinous adenocarcinoma (27.8% vs. 6.5%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.014), and be larger in size (\u2265 5 cm: 55.6% vs. 30.6%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.048). Conversely, dMMR status was linked to a suggestively significantly lower rate of lymph node metastasis (22.2% vs. 46.8%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.052). Forward stepwise multivariable analysis confirmed right colon location (OR = 4.12), poor differentiation (OR = 3.45), and mucinous histology (OR = 3.01) as independent predictors of dMMR. Notably, isolated MSH6 loss was suggestively associated with younger age and poor differentiation, but these findings are preliminary due to the small number of cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prevalence of dMMR in this cohort was 22.5%. dMMR CRCs display a distinct clinicopathological profile characterized by right-sided location, poor differentiation, mucinous histology, larger tumor size, along with a lower likelihood of lymph node metastasis. These findings support the value of routine IHC-based MMR testing in CRC patients. However, confirmatory molecular testing (e.g., MSI analysis, BRAF V600E mutation, MLH1 promoter methylation, or germline sequencing) is necessary to differentiate sporadic from Lynch syndrome-associated dMMR cases and to fully guide Lynch syndrome screening and immunotherapy decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1840244","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:40:34Z","timestamp":1781239234000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Relationship between MLH1, MSH2, MSH6, and PMS2 protein expression status and clinicopathological characteristics in colorectal cancer tissues"],"prefix":"10.3389","volume":"13","author":[{"given":"Wansheng","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Pathology, Zongyang County People\u2019s Hospital, Tongling","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zongyang County People\u2019s Hospital, Tongling","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyun","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zongyang County People\u2019s Hospital, Tongling","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zongyang County People\u2019s Hospital, Tongling","place":["Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics.","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"105142","DOI":"10.1016\/j.ebiom.2024.105142","article-title":"Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.","volume":"103","author":"Xu","year":"2024","journal-title":"EBioMedicine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5735-5747.e15","DOI":"10.1016\/j.cell.2025.07.003","article-title":"DNA mutagenesis driven by transcription factor competition with mismatch repair.","volume":"188","author":"Zhu","year":"2025","journal-title":"Cell."},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-025-02846-x","article-title":"MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade glioma.","volume":"149","author":"Friker","year":"2025","journal-title":"Acta Neuropathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41571-025-01054-6","article-title":"Therapeutic targeting of mismatch repair-deficient cancers.","volume":"22","author":"Johannet","year":"2025","journal-title":"Nat Rev Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"154647","DOI":"10.1016\/j.prp.2023.154647","article-title":"Heterogeneous expression of mismatch repair proteins and interpretation of immunohistochemical results in colorectal cancer and endometrial cancer.","volume":"248","author":"Li","year":"2023","journal-title":"Pathol Res Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1414376","DOI":"10.3389\/fimmu.2024.1414376","article-title":"Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms.","volume":"15","author":"Majumder","year":"2024","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e71838","DOI":"10.1002\/hsr2.71838","article-title":"Enhancing immunotherapy in lung cancer: the promise of dMMR\/MSI-H tumors and immune checkpoint inhibitors.","volume":"9","author":"Mohiuddin","year":"2026","journal-title":"Health Sci Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.23736\/s2724-5691.23.09854-4","article-title":"Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside.","volume":"78","author":"Kanani","year":"2023","journal-title":"Minerva Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1019582","DOI":"10.3389\/fimmu.2022.1019582","article-title":"Clinicopathological characteristics of high microsatellite instability\/mismatch repair-deficient colorectal cancer: a narrative review.","volume":"13","author":"Mei","year":"2022","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.7150\/jca.81675","article-title":"Microsatellite status detection of colorectal cancer: evaluation of inconsistency between PCR and IHC.","volume":"14","author":"Chen","year":"2023","journal-title":"J Cancer."},{"key":"B13","first-page":"254","article-title":"[Analysis of microsatellite instability in endometrial cancer: the significance of minimal microsatellite shift].","volume":"55","author":"Liang","year":"2023","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban."},{"key":"B14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.5152\/tjg.2024.23366","article-title":"The Relationship between DNA mismatch repair status and clinicopathologic characteristics in colon cancer.","volume":"35","author":"Do\u011fan","year":"2024","journal-title":"Turk J Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.21873\/anticanres.18043","article-title":"Risk of non-colorectal malignancies in sporadic versus lynch syndrome-associated dMMR colorectal cancer.","volume":"46","author":"Gkekas","year":"2026","journal-title":"Anticancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/cam4.3688","article-title":"Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.","volume":"10","author":"Hodan","year":"2021","journal-title":"Cancer Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"808964","DOI":"10.3389\/fimmu.2021.808964","article-title":"Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy.","volume":"12","author":"Bai","year":"2021","journal-title":"Front Immunol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:40:39Z","timestamp":1781239239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1840244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1840244"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1840244","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1840244"}}